Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma

The crosstalk among the complement system, immune cells, and mediators of inflammation provides an efficient mechanism to protect the organism against infections and support the repair of damaged tissues. Alterations in this complex machinery play a role in the pathogenesis of different diseases. Core complement proteins C3 and C5, their activation fragments, their receptors, and their regulators have been shown to be active intracellularly as the complosome. The kidney is particularly vulnerable to complement-induced damage, and emerging findings have revealed the role of complement system dysregulation in a wide range of kidney disorders, including glomerulopathies and ischemia-reperfusion injury during kidney transplantation. Different studies have shown that activation of the complement system is an important component of tumorigenesis and its elements have been proved to be present in the TME of various human malignancies. The role of the complement system in renal cell carcinoma (RCC) has been recently explored. Clear cell and papillary RCC upregulate most of the complement genes relative to normal kidney tissue. The aim of this narrative review is to provide novel insights into the role of complement in kidney disorders.

[1]  J. Thurman,et al.  The role of complement in kidney disease , 2023, Nature Reviews Nephrology.

[2]  J. Lv,et al.  Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy , 2023, Clinical journal of the American Society of Nephrology : CJASN.

[3]  P. Ditonno,et al.  Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers , 2023, International journal of molecular sciences.

[4]  G. Choukroun,et al.  Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease , 2023, Frontiers in immunology.

[5]  N. Sheerin,et al.  Complement activation and kidney transplantation; a complex relationship. , 2023, Immunobiology.

[6]  P. Ditonno,et al.  Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma , 2023, Journal of clinical medicine.

[7]  Benjamin Wooden,et al.  Complement inhibitors for kidney disease. , 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  M. Coughlan,et al.  Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease , 2023, International journal of molecular sciences.

[9]  Parul Singh,et al.  Complement, complosome, and complotype: A perspective , 2023, European journal of immunology.

[10]  C. Kemper,et al.  Complosome — the intracellular complement system , 2023, Nature Reviews Nephrology.

[11]  P. Ditonno,et al.  Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice , 2023, Biomedicines.

[12]  P. Ditonno,et al.  The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery , 2023, Expert review of molecular diagnostics.

[13]  Songqing He,et al.  The role of the complosome in health and disease , 2023, Frontiers in Immunology.

[14]  D. Ribatti,et al.  MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation , 2023, International journal of molecular sciences.

[15]  M. López-Nevot,et al.  Complement Binding Anti-HLA Antibodies and the Survival of Kidney Transplantation , 2023, Journal of clinical medicine.

[16]  S. Aiello,et al.  The Complement System in Kidney Transplantation , 2023, Cells.

[17]  M. Säemann,et al.  Novel aspects in the pathophysiology and diagnosis of glomerular diseases , 2022, Annals of the Rheumatic Diseases.

[18]  C. Daniel,et al.  Complement Inhibition in Kidney Transplantation: Where Are We Now? , 2022, BioDrugs.

[19]  P. Ditonno,et al.  Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets , 2022, International journal of molecular sciences.

[20]  P. Ditonno,et al.  MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome , 2022, International journal of molecular sciences.

[21]  Yan-jun Zhu,et al.  Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. , 2022, Urologic oncology.

[22]  G. Strada,et al.  The cross‐talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells , 2022, FEBS letters.

[23]  A. Bagga,et al.  Haemolytic uraemic syndrome , 2022, The Lancet.

[24]  A. Blom,et al.  Intracellular complement: Evidence, definitions, controversies, and solutions , 2022, Immunological reviews.

[25]  F. Bray,et al.  Epidemiology of Renal Cell Carcinoma: 2022 Update. , 2022, European urology.

[26]  M. Kolev,et al.  Inside-Out of Complement in Cancer , 2022, Frontiers in Immunology.

[27]  P. Lund,et al.  Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Reinhard,et al.  Membranous nephropathy: new pathogenic mechanisms and their clinical implications , 2022, Nature Reviews Nephrology.

[29]  Beata Franczyk,et al.  Renal Cell Cancer and Obesity , 2022, International journal of molecular sciences.

[30]  Weijun Qin,et al.  Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application , 2022, Frontiers in Immunology.

[31]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[32]  G. Giardino,et al.  Inherited defects in the complement system , 2022, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[33]  M. Ruseva,et al.  Mitochondrial C5aR1 activity in macrophages controls IL-1β production underlying sterile inflammation , 2021, Science Immunology.

[34]  S. Wen,et al.  Intracellular C3 prevents hepatic steatosis by promoting autophagy and very‐low‐density lipoprotein secretion , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  H. Jägle,et al.  Complement Factor H-Related 3 Enhanced Inflammation and Complement Activation in Human RPE Cells , 2021, Frontiers in Immunology.

[36]  Weimin Ma,et al.  Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma , 2021, BMC Cancer.

[37]  Sarah E. Street,et al.  Renal Cell Cancer and Chronic Kidney Disease. , 2021, Advances in chronic kidney disease.

[38]  M. Pickering,et al.  Complement activation in IgA nephropathy , 2021, Seminars in Immunopathology.

[39]  S. Neelamegham,et al.  Local Complement Factor H protects kidney endothelial cell structure and function. , 2021, Kidney international.

[40]  Yung-Ming Chen,et al.  Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients , 2021, Frontiers in Immunology.

[41]  P. Ditonno,et al.  Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation , 2021, Transplantology.

[42]  P. Validire,et al.  Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade , 2021, Cancer Immunology Research.

[43]  P. Validire,et al.  Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s , 2021, Cancer Immunology Research.

[44]  L. Gesualdo,et al.  Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury , 2021, Aging.

[45]  G. Beeson,et al.  Mitochondrial C3a Receptor Activation in Oxidatively Stressed Epithelial Cells Reduces Mitochondrial Respiration and Metabolism , 2021, Frontiers in Immunology.

[46]  Chunhua Huang,et al.  CD46 splice variant enhances translation of specific mRNAs linked to an aggressive tumor cell phenotype in bladder cancer , 2021, Molecular therapy. Nucleic acids.

[47]  D. Portilla,et al.  Role of intracellular complement activation in kidney fibrosis , 2021, British journal of pharmacology.

[48]  H. Debiec,et al.  Advances in Membranous Nephropathy , 2021, Journal of clinical medicine.

[49]  C. Porta,et al.  Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma , 2020, Metabolites.

[50]  J. Brugarolas,et al.  Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma , 2020, The Journal of Immunology.

[51]  C. Sautès-Fridman,et al.  Complement System: Promoter or Suppressor of Cancer Progression? , 2020, Antibodies.

[52]  M. Accetturo,et al.  DelCFHR3‐1 influences graft survival in transplant patients with IgA nephropathy via complement‐mediated cellular senescence , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  J. Pascual,et al.  Activation of final complement components after kidney transplantation as a marker of delayed graft function severity , 2020, Clinical kidney journal.

[54]  N. Merle,et al.  Complement's favourite organelle—Mitochondria? , 2020, British Journal of Pharmacology.

[55]  G. Bovo,et al.  36 kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in clear cell Renal Cell Carcinoma Cells. , 2020, The American journal of pathology.

[56]  H. Lee,et al.  Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis , 2020, Lupus.

[57]  L. Gesualdo,et al.  PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma , 2020, Aging.

[58]  C. Viret,et al.  Regulation of anti-microbial autophagy by factors of the complement system , 2020, Microbial cell.

[59]  J. Thurman Complement and the Kidney: An Overview. , 2020, Advances in chronic kidney disease.

[60]  S. Kulkarni,et al.  Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  P. Zipfel,et al.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. , 2020, Journal of the American Society of Nephrology : JASN.

[62]  C. Shu,et al.  C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts , 2020, Journal of Experimental & Clinical Cancer Research.

[63]  S. Jordan,et al.  Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[64]  J. Cesbron,et al.  The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease , 2019, Clinical Reviews in Allergy & Immunology.

[65]  P. Cravedi,et al.  Complement and Complement Targeting Therapies in Glomerular Diseases , 2019, International journal of molecular sciences.

[66]  Yupei Zhao,et al.  Role of the complement system in the tumor microenvironment , 2019, Cancer Cell International.

[67]  I. Maillard,et al.  Notch signalling in T cell homeostasis and differentiation , 2019, Open Biology.

[68]  A. Hakimi,et al.  Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. , 2019, Cancer discovery.

[69]  C. Sautès-Fridman,et al.  Context-dependent roles of complement in cancer , 2019, Nature Reviews Cancer.

[70]  P. Sansonetti,et al.  100th Anniversary of Jules Bordet's Nobel Prize: Tribute to a Founding Father of Immunology , 2019, Front. Immunol..

[71]  L. Gesualdo,et al.  Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/βcatenin signaling after ischemia/reperfusion injury , 2019, Aging.

[72]  Kun-yi Wu,et al.  The C5a/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia/reperfusion injury. , 2019, Kidney international.

[73]  A. Pircher,et al.  Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy , 2019, Front. Oncol..

[74]  P. Validire,et al.  Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth , 2019, Cancer Immunology Research.

[75]  D. Ribatti,et al.  Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. , 2019, Urologic oncology.

[76]  A. Blom,et al.  Interaction of Serum-Derived and Internalized C3 With DNA in Human B Cells—A Potential Involvement in Regulation of Gene Transcription , 2019, Front. Immunol..

[77]  A. Blom,et al.  Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. , 2019, JCI insight.

[78]  P. Garred,et al.  Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4+ T cells. , 2019, Immunobiology.

[79]  A. Blom,et al.  Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1 , 2019, Autophagy.

[80]  Y. Wan,et al.  Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages , 2018, Cancer Immunology Research.

[81]  D. Ribatti,et al.  Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma , 2018, Aging.

[82]  M. Haas,et al.  A phase I/II, double‐blind, placebo‐controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[83]  Jan U. Becker,et al.  A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology , 2018, Transplantation.

[84]  M. Pirooznia,et al.  Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism , 2018, Nature Communications.

[85]  Adam A. Margolin,et al.  Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. , 2018, Cancer cell.

[86]  P. Ditonno,et al.  The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma , 2018, Translational Cancer Research.

[87]  M. Markiewski,et al.  Complementing Cancer Metastasis , 2018, Front. Immunol..

[88]  L. Gesualdo,et al.  Complement Activation During Ischemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling , 2018, Front. Immunol..

[89]  D. Philpott,et al.  Complement C3 Drives Autophagy-Dependent Restriction of Cyto-invasive Bacteria. , 2018, Cell host & microbe.

[90]  M. Kolev,et al.  Complement and the Regulation of T Cell Responses. , 2018, Annual review of immunology.

[91]  C. Garlanda,et al.  PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. , 2018, Physiological reviews.

[92]  O. Dymova,et al.  A prospective randomized, controlled trial of eculizumab to prevent ischemia‐reperfusion injury in pediatric kidney transplantation , 2018, Pediatric transplantation.

[93]  Z. Fishelson,et al.  Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9 , 2018, Cell Death & Disease.

[94]  R. Weiss,et al.  The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation , 2017, Oncotarget.

[95]  R. Pio,et al.  Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment. , 2017, Seminars in cell & developmental biology.

[96]  C. Farrar,et al.  Complement Recognition Pathways in Renal Transplantation. , 2017, Journal of the American Society of Nephrology : JASN.

[97]  Dirk Sieger,et al.  Complement as a regulator of adaptive immunity , 2017, Seminars in Immunopathology.

[98]  P. van Paassen,et al.  Complement in ANCA-associated glomerulonephritis , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[99]  E. Salvaris,et al.  Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice , 2017, The Journal of Immunology.

[100]  L. Trouw,et al.  Production of complement components by cells of the immune system , 2017, Clinical and experimental immunology.

[101]  J. Atkinson,et al.  A C3(H20) recycling pathway is a component of the intracellular complement system , 2017, The Journal of clinical investigation.

[102]  V. Afshar-Kharghan The role of the complement system in cancer , 2017, The Journal of clinical investigation.

[103]  Ming-hui Zhao,et al.  Complement Alternative Pathway's Activation in Patients With Lupus Nephritis , 2017, The American journal of the medical sciences.

[104]  Wei Zhang,et al.  CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance , 2016, Stem cell reports.

[105]  C. Hess,et al.  Complement-Mediated Regulation of Metabolism and Basic Cellular Processes. , 2016, Immunity.

[106]  M. Battaglia,et al.  Multi-omics approach reveals the secrets of metabolism of clear cell—renal cell carcinoma , 2016, Translational andrology and urology.

[107]  A. Sher,et al.  T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells , 2016, Science.

[108]  Wuding Zhou,et al.  Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. , 2016, The Journal of clinical investigation.

[109]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[110]  S. Gandini,et al.  Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis , 2016, Nature Communications.

[111]  G. Ardissino,et al.  Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. , 2016, Kidney international.

[112]  G. Remuzzi,et al.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. , 2016, Molecular immunology.

[113]  A. Sood,et al.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial–Mesenchymal Transition , 2016, The Journal of Immunology.

[114]  Xian Shen,et al.  C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition. , 2016, Experimental and molecular pathology.

[115]  F. Schena,et al.  Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics , 2016, Diseases.

[116]  M. Accetturo,et al.  Complement Modulation of Anti‐Aging Factor Klotho in Ischemia/Reperfusion Injury and Delayed Graft Function , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[117]  J. Thurman,et al.  The Complement System and Antibody-Mediated Transplant Rejection , 2015, The Journal of Immunology.

[118]  D. Ribatti,et al.  Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell–Renal Cell Carcinoma , 2015, Medicine.

[119]  C. Legendre,et al.  The emerging role of complement inhibitors in transplantation. , 2015, Kidney international.

[120]  M. Salvadori,et al.  Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. , 2015, World journal of transplantation.

[121]  M. Kolev,et al.  Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses , 2015, Immunity.

[122]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[123]  Lubka T. Roumenina,et al.  Complement System Part II: Role in Immunity , 2015, Front. Immunol..

[124]  D. Ribatti,et al.  Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma , 2015, Oncotarget.

[125]  Y. Kawano,et al.  C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. , 2015, Oncology reports.

[126]  J. Atkinson,et al.  Complement regulators in human disease: lessons from modern genetics , 2015, Journal of internal medicine.

[127]  M. Battaglia,et al.  The Role of Renal Surgery in the Era of Targeted Therapy: The Urologist's Perspective , 2015, Urologia.

[128]  John D Lambris,et al.  PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer , 2015, Cell.

[129]  M. Haas,et al.  A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients , 2015, Transplantation.

[130]  L. Gesualdo,et al.  Pre-existing Type 2 Diabetes Mellitus Is an Independent Risk Factor for Mortality and Progression in Patients With Renal Cell Carcinoma , 2014, Medicine.

[131]  A. Tenner,et al.  Complement modulation of T cell immune responses during homeostasis and disease , 2014, Journal of leukocyte biology.

[132]  Wuding Zhou,et al.  Mannan‐binding lectin‐associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4 , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[133]  C. Tripodo,et al.  Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice , 2014, Leukemia.

[134]  Loreto Gesualdo,et al.  A Single-Center Cohort Study to Define the Role of Pretransplant Biopsy Score in the Long-term Outcome of Kidney Transplantation , 2014, Transplantation.

[135]  L. Gesualdo,et al.  Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[136]  Ming-hui Zhao,et al.  The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease , 2014, PloS one.

[137]  K. Baggerly,et al.  Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.

[138]  K. Wood,et al.  Induction of transplantation tolerance through regulatory cells: from mice to men , 2014, Immunological reviews.

[139]  L. Gesualdo,et al.  Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma , 2014, Disease markers.

[140]  D. G. Sandor,et al.  The role of complement in membranous nephropathy. , 2013, Seminars in nephrology.

[141]  C. Legendre,et al.  Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. , 2013, Transplantation reviews.

[142]  Jie Gu,et al.  Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. , 2013, Lung cancer.

[143]  L. Rostaing,et al.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[144]  J. Lindeman,et al.  Acute But Transient Release of Terminal Complement Complex After Reperfusion in Clinical Kidney Transplantation , 2013, Transplantation.

[145]  Feng Yu,et al.  Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. , 2012, Rheumatology.

[146]  L. Domański,et al.  Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[147]  G. Remuzzi,et al.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation , 2012, Nature Reviews Nephrology.

[148]  John D Lambris,et al.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. , 2012, Neoplasia.

[149]  P. Handford,et al.  The CD46 and Jagged1 interaction is critical for human T helper 1 immunity , 2012, Nature Immunology.

[150]  M. Carroll,et al.  Regulation of humoral immunity by complement. , 2012, Immunity.

[151]  P. Morgado,et al.  Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells , 2012, The Journal of Immunology.

[152]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[153]  Jinhua Lu,et al.  C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulation. , 2011, Molecular immunology.

[154]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[155]  M. Sughrue,et al.  Cancer and the Complement Cascade , 2010, Molecular Cancer Research.

[156]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[157]  P. Ditonno,et al.  Extended criteria donor kidney transplantation: comparative outcome analysis between single versus double kidney transplantation at 5 years. , 2010, Transplantation proceedings.

[158]  M. Daha,et al.  Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. , 2010, The American journal of pathology.

[159]  F. Casagrande,et al.  In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma , 2009, British Journal of Cancer.

[160]  D. Lambrechts,et al.  Thrombomodulin mutations in atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[161]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.

[162]  P. Heeger,et al.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. , 2008, Blood.

[163]  G. Dubyak,et al.  Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. , 2008, Immunity.

[164]  B. Boudailliez,et al.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[165]  A. Jevnikar,et al.  Preventing Renal Ischemia–Reperfusion Injury Using Small Interfering RNA by Targeting Complement 3 Gene , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[166]  W. Fridman,et al.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.

[167]  M. Nangaku,et al.  Critical Protection from Renal Ischemia Reperfusion Injury by CD55 and CD591 , 2004, The Journal of Immunology.

[168]  G. Remuzzi,et al.  Familial haemolytic uraemic syndrome and an MCP mutation , 2003, The Lancet.

[169]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[170]  M. Walport Complement. First of two parts. , 2001, The New England journal of medicine.

[171]  D. Pérez-Caballero,et al.  Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. , 2001, American journal of human genetics.

[172]  B. Julian,et al.  Complement activation in IgA nephropathy. , 1987, Kidney international.

[173]  H. Coovadia,et al.  C3 metabolism in acute glomerulonephritis: implications for sites of complement activation. , 1984, Kidney international.

[174]  G. Remuzzi,et al.  Kidney diseases , 1913, Immunological reviews.

[175]  Handbook of Cancer and Immunology , 2022 .

[176]  T. Freiwald,et al.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics. , 2021, Advances in immunology.

[177]  M. Presta,et al.  Long pentraxin 3: A novel multifaceted player in cancer. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[178]  M. Kirschfink,et al.  The complement system in cancer: Ambivalence between tumour destruction and promotion. , 2017, Immunobiology.

[179]  L. Gesualdo,et al.  Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population , 2014, World Journal of Urology.

[180]  B. Ranchin,et al.  C3 nephritic factor associated with C3 glomerulopathy in children , 2013, Pediatric Nephrology.

[181]  P. Ditonno,et al.  Obesity in kidney transplantation affects renal function but not graft and patient survival. , 2011, Transplantation proceedings.